Pierre-Fabre fails to provide enough clinical evidence to convince NICE about Javlor
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, says that it will not, for the time being, be recommending Pierre-Fabre's vinca alkaloid anticancer, Javlor (vinflunine), as a second-line treatment for bladder cancer because there is not enough evidence to show that the drug is clinically effective.